EGFR and non-small cell lung carcinoma: To analyze the inhibitory effect of HM90822B on IAP proteins, we examined the protein expression levels of several IAP proteins after treatment with HM90822B in various NSCLC cells, including cells with EGFR tyrosine-kinase inhibitor (TKI)-resistant mutations, such as H1975 and PC-9GR (Figure 2c).